Inotrem expands Series B
Paris-based Inotrem S.A., which specializes in immunotherapy for acute and chronic inflammatory syndromes, has expanded its Series B funding to 58 million euros.
Paris-based Inotrem S.A., which specializes in immunotherapy for acute and chronic inflammatory syndromes, has expanded its Series B funding to 58 million euros.
Copyright PEI Media
Not for publication, email or dissemination
